drugset / Trial / NCT03337451
Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome
Phase 1/2
Completed
14 enrolled
Opsona Therapeutics Ltd.
H. Lee Moffitt Cancer Center and Research Institute · collabM.D. Anderson Cancer Center · collabMontefiore Medical Center · collabNew York Presbyterian Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This protocol is a follow-up for patients receiving continuation of OPN-305 monotherapy treatment or combination treatment with azacitidine after completion of the dose confirming, dose expansion and HMA naïve parts of the main study OPN-305-106.
Timeline
- Start
- 2018-02-27
- Primary completion
- 2019-01-10
- Completion
- 2019-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TOMARALIMAB | Monoclonal antibody | — | Intravenous |